BUZZ-Psychedelic drug developer Atai rises as RFK Jr picked for top US health agency role

Reuters

Nov 15, 2024

BUZZ-Psychedelic drug developer Atai rises as RFK Jr picked for top US health agency role

** U.S.-listed shares of psychedelics-based drug developer atai Life Sciences 9VC.F, ATAI.O rise 11.7% to $1.53 premarket

** President-elect Donald Trump selects Robert F. Kennedy Jr. to lead the Department of Health and Human Services

** Kennedy has previously criticized the U.S. FDA over its "aggressive suppression" of psychedelics

** ATAI has several drugs in development that are based on psychedelic drugs, including VLS-01 for treatment-resistant depression that is a formulation of dimethyltryptamine, or DMT, and EMP-01 for social anxiety disorder that uses a form of MDMA

** "RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development," and appears to recognize "responsible" use of MDMA, Jefferies analyst Andrew Tsai said in a note on Monday

** Brokerage notes programs from cos such as ATAI, Compass Pathways CMPS.O and GH Research GHRS.O that are using pyschedelic-based drugs

** Up to last close, ATAI shares had fallen 2.8% YTD versus a 5.4% increase in the Nasdaq Biotechnology index .NBI

(Reporting by Leroy Leo in Bengaluru)

((Leroy.Dsouza@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2483732252"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483732252\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2483732252?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483732252","market":"us","top_or_hot":-1,"title":"BUZZ-Psychedelic drug developer Atai rises as RFK Jr picked for top US health agency role","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Psychedelic drug developer Atai rises as RFK Jr picked for top US health agency role</title></head><body><p>** U.S.-listed shares of psychedelics-based drug developer atai Life Sciences <span>9VC.F</span>, <span>ATAI.O</span> rise 11.7% to $1.53 premarket </p><p>** President-elect Donald Trump selects <span>Robert F. Kennedy Jr.</span> to lead the Department of Health and Human Services</p><p>** Kennedy has previously criticized the U.S. FDA over its \"aggressive suppression\" of psychedelics</p><p>** ATAI has several drugs in development that are based on psychedelic drugs, including VLS-01 for treatment-resistant depression that is a formulation of dimethyltryptamine, or DMT, and EMP-01 for social anxiety disorder that uses a form of MDMA</p><p>** \"RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development,\" and appears to recognize \"responsible\" use of MDMA, Jefferies analyst Andrew Tsai said in a note on Monday</p><p>** Brokerage notes programs from cos such as ATAI, Compass Pathways <span>CMPS.O</span> and GH Research <span>GHRS.O</span> that are using pyschedelic-based drugs</p><p>** Up to last close, ATAI shares had fallen 2.8% YTD versus a 5.4% increase in the Nasdaq Biotechnology index <span>.NBI</span></p><p> (Reporting by Leroy Leo in Bengaluru)</p><p> ((Leroy.Dsouza@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Psychedelic drug developer Atai rises as RFK Jr picked for top US health agency role</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Psychedelic drug developer Atai rises as RFK Jr picked for top US health agency role\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-15 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Psychedelic drug developer Atai rises as RFK Jr picked for top US health agency role</title></head><body><p>** U.S.-listed shares of psychedelics-based drug developer atai Life Sciences <span>9VC.F</span>, <span>ATAI.O</span> rise 11.7% to $1.53 premarket </p><p>** President-elect Donald Trump selects <span>Robert F. Kennedy Jr.</span> to lead the Department of Health and Human Services</p><p>** Kennedy has previously criticized the U.S. FDA over its \"aggressive suppression\" of psychedelics</p><p>** ATAI has several drugs in development that are based on psychedelic drugs, including VLS-01 for treatment-resistant depression that is a formulation of dimethyltryptamine, or DMT, and EMP-01 for social anxiety disorder that uses a form of MDMA</p><p>** \"RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development,\" and appears to recognize \"responsible\" use of MDMA, Jefferies analyst Andrew Tsai said in a note on Monday</p><p>** Brokerage notes programs from cos such as ATAI, Compass Pathways <span>CMPS.O</span> and GH Research <span>GHRS.O</span> that are using pyschedelic-based drugs</p><p>** Up to last close, ATAI shares had fallen 2.8% YTD versus a 5.4% increase in the Nasdaq Biotechnology index <span>.NBI</span></p><p> (Reporting by Leroy Leo in Bengaluru)</p><p> ((Leroy.Dsouza@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPS","symbol_name":"COMPASS Pathways plc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL4N3MM0TS:1","article_id":"2483732252","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483732252","pubTimestamp":1731672391,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Psychedelic drug developer Atai rises as RFK Jr picked for top US health agency role** U.S.-listed shares of psychedelics-based drug developer atai Life Sciences 9VC.F, ATAI.O rise 11.7% to $1.53 premarket ** President-elect Donald Trump selects Robert F. Kennedy Jr. to lead the Department of Health and Human Services** Kennedy has previously criticized the U.S. FDA over its \"aggressive suppression\" of psychedelics** ATAI has several drugs in development that are based on psychedelic drugs, including VLS-01 for treatment-resistant depression that is a formulation of dimethyltryptamine, or DMT, and EMP-01 for social anxiety disorder that uses a form of MDMA** \"RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development,\" and appears to recognize \"responsible\" use of MDMA, Jefferies analyst Andrew Tsai said in a note on Monday** Brokerage notes programs from cos such as ATAI, Compass Pathways CMPS.O and GH Research GHRS.O that are using pyschede","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPS":"COMPASS Pathways plc","BK4007":"制药","GHRS":"GH Research PLC","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"嗡嗡声-迷幻药开发商Atai崛起，RFK Jr被选为美国卫生机构最高职位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GHRS":0.9,"CMPS":0.9},"content_text":"BUZZ-Psychedelic drug developer Atai rises as RFK Jr picked for top US health agency role** U.S.-listed shares of psychedelics-based drug developer atai Life Sciences 9VC.F, ATAI.O rise 11.7% to $1.53 premarket ** President-elect Donald Trump selects Robert F. Kennedy Jr. to lead the Department of Health and Human Services** Kennedy has previously criticized the U.S. FDA over its \"aggressive suppression\" of psychedelics** ATAI has several drugs in development that are based on psychedelic drugs, including VLS-01 for treatment-resistant depression that is a formulation of dimethyltryptamine, or DMT, and EMP-01 for social anxiety disorder that uses a form of MDMA** \"RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development,\" and appears to recognize \"responsible\" use of MDMA, Jefferies analyst Andrew Tsai said in a note on Monday** Brokerage notes programs from cos such as ATAI, Compass Pathways CMPS.O and GH Research GHRS.O that are using pyschedelic-based drugs** Up to last close, ATAI shares had fallen 2.8% YTD versus a 5.4% increase in the Nasdaq Biotechnology index .NBI (Reporting by Leroy Leo in Bengaluru) ((Leroy.Dsouza@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}